Menu of Tests

The PGXL Multi-Drug Sensitivity Panel

While we test individual genes, the real benefit of pharmacogenomics lies in the interplay between multiple genes and multiple drugs. PGXL’s broad spectrum drug sensitivity panel gives a unique, 360-degree view of each patient. It covers the genes known to determine the efficacy of 95% of medications, identifies patients susceptible to adverse events and red-flags drug interactions that complicate the patient’s care.

In addition to the panel, PGXL tests individual genes for both clinical and research purposes. Below is a list of tests currently available.

Pharmacogenetics

CYP2D6
CYP2C19
CYP2C9
CYP3A4
CYP3A5
CYP1A2
VKORC1
SLC6A4
OPRM1
SLCO1B1
MTHFR
COMT
Factor II (Prothrombin 20210 G>A)
FactorNAT2
HLA-B*5701 V Leiden

Molecular Oncology  –  For Research Inquiries Only

KRAS
BRAF
BCR/ABL (quantitative)
BCR/ABL Kinase Domain mutations
BCL1
BCL2
PML-RARa
c-KIT
EGFR
EGFR (FISH)
JAK2
ALK (FISH)
DPD/TYMS
TPMT
CYP2D6 tamoxifen

 

 

 

 

For sample collection and ordering instructions, download our Collection and Shipment Guide